Benchmark

In a report published Friday, Benchmark reiterated its Hold rating on The New York Times Company (NYSE: NYT), and slightly raised its price target from $8.00 to $9.00. Benchmark noted, “New York Times (NYT-Hold, PT from $8 to $9) reported 4Q12 revenues of $576 million, up 5% y/y and slightly above...

In a report published Friday, Benchmark reiterated its Buy rating on Guidance Software (NASDAQ: GUID), but lowered its price target to $13.00. Benchmark noted, “We expect GUID to come under pressure today after the Company reported mixed 4Q12 results (EPS was in line but revenue missed) and after...

In a report published Friday, Benchmark reiterated its Buy rating on Coinstar (NASDAQ: CSTR), but lowered its price target from $85.00 to $65.00. Benchmark noted, “DVD comps are expected to decline through the first half of the year. We decreased our FY13 EPS estimate to $5.35, from $5.80 and...

Benchmark downgraded Vascular Solutions (NASDAQ: VASC) from Buy to Hold and announced a $17.00 price target. Benchmark commented, "We are downgrading Vascular Solutions to a Hold rating from a Buy rating based on valuation as VASC is trading close to our $17.00 price target. Our $17.00 price...

Benchmark downgraded American Science & Engineering (NASDAQ: ASEI) from Buy to Hold and announced a $65.00 price target. Benchmark noted, "We are downgrading AS&E to a HOLD with a new Price Target of $65. 1) We believe AS&E will struggle to grow in FY13 and possibly in FY14 due to...

Benchmark downgraded BioClinica, Inc (NASDAQ: BIOC) from Buy to Hold and maintained a $7.25 price target. Benchmark said, "BioClinica announced it has entered into a definitive agreement with the private equity firm, JLL Partners, to acquire BioClinica for $7.25 per share. This reflects 1.6x our...

Benchmark initiated coverage on Omnicell (NASDAQ: OMCL) with a Buy rating and a $19.00 price target. Benchmark commented, "We are initiating coverage of Omnicell at Buy with a $19 price target based on an 18x multiple of $1.05 in EPS we forecast this year. Omnicell offers a good mix of visibility...

Benchmark initiated coverage on Perion Networks (NASDAQ: PERI) with a Buy rating and a $17.00 price target. Benchmark commented, "We like Perion for the following reasons: 1) we believe Perion can record sustainable organic growth of 20-25% through accelerating search revenue and increasing...

Benchmark upgraded Healthcare Services Group, Inc. (NASDAQ: HCSG) from Hold to Buy and raised the price target from $23.50 to $27.00. Benchmark said, "We believe that visibility is improving as it relates to some of the headwinds that were facing HCSG going into 2013. The first headwind with...

Benchmark reiterated its Speculative Buy rating on Cardiovascular Systems (NASDAQ: CSII) and increased its price target from $13.50 to $18. Benchmark said, "We believe that there is a significant market opportunity in the U.S. for CSII to launch their device in the coronary market during calendar...

Benchmark reiterated its Buy rating on EW Scripps (NYSE: SSP) and raised its price target from $11 to $13. Benchmark noted, "Scripps trades at 4x 2013E EBITDA, at a discount to publishing peers. We believe a premium is warranted given the increased importance of broadcasting. Based on 5x our...

Benchmark lowered its rating on LivePerson (NASDAQ: LPSN) from Buy to Hold with a $13 price target. Benchmark commented, "We are downgrading our rating on LPSN to Hold from Buy and resetting our price target to $13 in the wake of last night's 3Q earnings report where the Company missed consensus...

Benchmark lowered its rating on MIPS Technologies (NASDAQ: MIPS) from Buy to Hold. Benchmark noted, "Early this morning, it was announced that: 1) MIPS will sell 498 patents to AST (a.k.a. Bridge Crossing) for $350 million, 2) Imagination Tech will buy the remaining 82 MIPS patents and MIPS...

Benchmark raised its rating on Symmetry Medical (NYSE: SMA) from Hold to Buy and increased its price target from $10 to $12. Benchmark commented, "We are upgrading SMA to a Buy rating from a Hold rating. Our upgrade is based on two factors. The first is that a significant part of our Hold...